Table 1 Summary of patient and treatment characteristics
N = 65 | |
|---|---|
Median (range) age, years | 71 (53–79) |
> 65 | 16 (25%) |
≤ 65 | 49 (75%) |
Median follow-up, months (range) | 55 (10–40) |
Median PSA, ng/mL (range) | 12.6 (3.2–68.7) |
< 10 | 22 (34%) |
10–20 | 20 (31%) |
> 20 | 23 (35%) |
Gleason Group 1 | 5 (8%) |
Group 2 | 13 (20%) |
Group 3 | 19 (29%) |
Group 4 | 20 (31%) |
Group 5 | 8 (12%) |
T stage T1 | 1 (2%) |
T2 | 17 (26%) |
T3 | 47 (72%) |
Number of high-risk factors 1 | 35 (54%) |
2 | 28 (43%) |
3 | 2 (3%) |
N stage N0 | 52 (80%) |
N1 | 13 (20%) |
Technique 3DCRT | 44 (68%) |
Technique IMRT | 21 (32%) |
Median dose 3DCRT, Gy (range) | 76.3 (74.78–79.16) |
Median dose IMRT Gy (range) | 81.7 (70.6–82-8) |